JP2012516879A - ＴＧＦ−β１阻害剤ペプチドの医薬処方物 - Google Patents

ＴＧＦ−β１阻害剤ペプチドの医薬処方物 Download PDF

Info

Publication number
JP2012516879A
JP2012516879A JP2011548731A JP2011548731A JP2012516879A JP 2012516879 A JP2012516879 A JP 2012516879A JP 2011548731 A JP2011548731 A JP 2011548731A JP 2011548731 A JP2011548731 A JP 2011548731A JP 2012516879 A JP2012516879 A JP 2012516879A
Authority
JP
Japan
Prior art keywords
tgf
cyclodextrin
emulsion
inhibitor peptide
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011548731A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012516879A5 (cg-RX-API-DMAC7.html
Inventor
ガレタ、ホアン マヌエル イラチェ
ガラン、フェルナンド マルティネス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Digna Biotech SL
Original Assignee
Digna Biotech SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Digna Biotech SL filed Critical Digna Biotech SL
Publication of JP2012516879A publication Critical patent/JP2012516879A/ja
Publication of JP2012516879A5 publication Critical patent/JP2012516879A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medical Informatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011548731A 2009-02-05 2010-02-04 ＴＧＦ−β１阻害剤ペプチドの医薬処方物 Pending JP2012516879A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200900319 2009-02-05
ESP200900319 2009-02-05
PCT/ES2010/070062 WO2010089443A2 (es) 2009-02-05 2010-02-04 FORMULACIONES FARMACÉUTICAS DE PÉPTIDOS INHIBIDORES DE TGF- β1

Publications (2)

Publication Number Publication Date
JP2012516879A true JP2012516879A (ja) 2012-07-26
JP2012516879A5 JP2012516879A5 (cg-RX-API-DMAC7.html) 2013-03-28

Family

ID=42320987

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011548731A Pending JP2012516879A (ja) 2009-02-05 2010-02-04 ＴＧＦ−β１阻害剤ペプチドの医薬処方物

Country Status (10)

Country Link
US (1) US20110294734A1 (cg-RX-API-DMAC7.html)
EP (1) EP2394666A2 (cg-RX-API-DMAC7.html)
JP (1) JP2012516879A (cg-RX-API-DMAC7.html)
CN (1) CN102307598A (cg-RX-API-DMAC7.html)
AU (1) AU2010210033A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI1008815A2 (cg-RX-API-DMAC7.html)
CA (1) CA2750559A1 (cg-RX-API-DMAC7.html)
MX (1) MX2011008261A (cg-RX-API-DMAC7.html)
RU (1) RU2011136694A (cg-RX-API-DMAC7.html)
WO (1) WO2010089443A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023549894A (ja) * 2020-12-23 2023-11-29 コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー ＴＧＦ－βシグナル伝達を抑制できる新規なペプチドおよびその用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012154567A2 (en) * 2011-05-06 2012-11-15 Albert Einstein College Of Medicine Of Yeshiva University Human invasion signature for prognosis of metastatic risk
AU2013337677B2 (en) 2012-11-02 2018-06-28 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
BR112015027569A2 (pt) * 2013-05-10 2017-09-19 Southern Res Inst compostos, composições, métodos e respectivos usos para tratar doenças por meio da inibição da atividade de tgf-ß
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
CN107533040B (zh) 2014-12-03 2022-03-29 细胞基因公司 激活素-actrii拮抗剂及用于治疗贫血症的用途
KR101841748B1 (ko) 2016-02-18 2018-05-08 (주)케어젠 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도
WO2019234221A1 (en) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
CN110483648A (zh) * 2019-08-27 2019-11-22 南京安吉生物科技有限公司 一种融合多肽及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5730969A (en) * 1988-10-05 1998-03-24 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
JP2002530431A (ja) * 1998-11-24 2002-09-17 インスティトゥト シエンティフィコ イ テクノロジコ デ ナバッラ，ソシエダ アノニマ ＴＧＦβ１−インヒビターペプチド
JP2007525204A (ja) * 2003-08-22 2007-09-06 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ トランスフォーミング増殖因子β１（ＴＧＦ−β１）との結合能を有するペプチド
US20070207965A1 (en) * 2006-03-01 2007-09-06 Digna Biotech, S.L. Method for the treatment of skin fibrosis and suitable compositions for such treatment
WO2008140594A2 (en) * 2006-12-01 2008-11-20 Anterios, Inc. Peptide nanoparticles and uses therefor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215520A (en) * 1991-09-17 1993-06-01 Centre Internationale De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) Method for delivering an active substance topically or percutaneously
US6132739A (en) * 1998-09-01 2000-10-17 Amway Corporation Makeup compositions and methods of making same
ES2371026T3 (es) * 2001-10-19 2011-12-26 Atritech, Inc. Dispositivo de oclusión ajustable en la orejuela auricular izquierda.
WO2003048323A2 (en) 2001-12-03 2003-06-12 Bristol-Myers Squibb Company Polynucleotides and polypeptides associated with the development of rheumatoid arthritis
ITRM20020119A1 (it) * 2002-03-05 2003-09-05 Geymonat Spa Composizioni contenenti plgf ad uso farmaceutico e cosmetico.
US7279503B1 (en) * 2004-11-02 2007-10-09 Siltech Llc Water in oil emulsions
AU2005337776B2 (en) 2005-10-24 2013-01-31 Proyecto De Biomedicina Cima, S.L. Use of TGF-Beta1 inhibitor peptides in the preparation of an immune response modulating agent
DE102006031500A1 (de) * 2006-07-06 2008-04-17 Henkel Kgaa O/W-Emulsion
WO2008013928A2 (en) 2006-07-28 2008-01-31 Biogen Idec Ma Inc. Treatment of cancer with interferon gene delivery in combination with a tgf-beta inhibitor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5730969A (en) * 1988-10-05 1998-03-24 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
JP2002530431A (ja) * 1998-11-24 2002-09-17 インスティトゥト シエンティフィコ イ テクノロジコ デ ナバッラ，ソシエダ アノニマ ＴＧＦβ１−インヒビターペプチド
JP2007525204A (ja) * 2003-08-22 2007-09-06 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ トランスフォーミング増殖因子β１（ＴＧＦ−β１）との結合能を有するペプチド
US20070207965A1 (en) * 2006-03-01 2007-09-06 Digna Biotech, S.L. Method for the treatment of skin fibrosis and suitable compositions for such treatment
WO2008140594A2 (en) * 2006-12-01 2008-11-20 Anterios, Inc. Peptide nanoparticles and uses therefor

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023549894A (ja) * 2020-12-23 2023-11-29 コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー ＴＧＦ－βシグナル伝達を抑制できる新規なペプチドおよびその用途
JP7686069B2 (ja) 2020-12-23 2025-05-30 コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー ＴＧＦ－βシグナル伝達を抑制できる新規なペプチドおよびその用途

Also Published As

Publication number Publication date
MX2011008261A (es) 2011-09-01
CN102307598A (zh) 2012-01-04
CA2750559A1 (en) 2010-08-12
BRPI1008815A2 (pt) 2018-02-14
AU2010210033A1 (en) 2011-08-04
RU2011136694A (ru) 2013-03-10
US20110294734A1 (en) 2011-12-01
WO2010089443A3 (es) 2010-10-21
WO2010089443A2 (es) 2010-08-12
EP2394666A2 (en) 2011-12-14

Similar Documents

Publication Publication Date Title
JP2012516879A (ja) ＴＧＦ−β１阻害剤ペプチドの医薬処方物
Kang et al. Thermoresponsive nanospheres with independent dual drug release profiles for the treatment of osteoarthritis
Akiyoshi et al. Self-assembled hydrogel nanoparticle of cholesterol-bearing pullulan as a carrier of protein drugs: complexation and stabilization of insulin
Cavalli et al. Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with β-cyclodextrins
JP3579060B2 (ja) アリール―複素環式化合物塩の包接錯体
Filipović-Grčić et al. Chitosan microspheres with hydrocortisone and hydrocortisone–hydroxypropyl-β-cyclodextrin inclusion complex
Liu et al. Hexapeptide-conjugated calcitonin for targeted therapy of osteoporosis
EP2143446A1 (en) Hybrid gel comprising chemically crosslinked hyaluronic acid derivative and pharmaceutical composition using the same
Silva et al. Solvent-free synthesis of acetylated cashew gum for oral delivery system of insulin
CN109789188A (zh) 具有低峰-谷比的pth化合物
Kang et al. Conformational stability of a model protein (bovine serum albumin) during primary emulsification process of PLGA microspheres synthesis
Jansook et al. Cyclodextrin solubilization of celecoxib: Solid and solution state characterization
Tavornvipas et al. Effects of cyclodextrins on chemically and thermally induced unfolding and aggregation of lysozyme and basic fibroblast growth factor
Altaani et al. Oral delivery of teriparatide using a nanoemulsion system: design, in vitro and in vivo evaluation
Khodaverdi et al. Casein-based hydrogel carrying insulin: preparation, in vitro evaluation and in vivo assessment
Shan et al. Locally controlled release of methotrexate and alendronate by thermo-sensitive hydrogels for synergistic inhibition of osteosarcoma progression
Liu et al. Osteotropic β-cyclodextrin for local bone regeneration
Urbanova et al. Molecular-level control of ciclopirox olamine release from poly (ethylene oxide)-based mucoadhesive buccal films: exploration of structure–property relationships with solid-state NMR
TW201842929A (zh) 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物
Gao et al. Empowering hydrophobic anticancer drugs by ultrashort peptides: General Co-assembly strategy for improved solubility, targeted efficacy, and clinical application
Hao et al. Self-assembled doxorubicin prodrug riding on the albumin express train enable tumor targeting and bio-activation
Silvestri et al. Physico-chemical studies of inclusion complex between hydrocortisone and cyclodextrins
Miles et al. Tyrosol derived poly (ester-arylate) s for sustained drug delivery from microparticles
Paul et al. Tricalcium phosphate delayed release formulation for oral delivery of insulin: a proof-of-concept study
Kim et al. Thermo-reversible flurbiprofen liquid suppository with HP-β-CD as a solubility enhancer: improvement of rectal bioavailability

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140916